Daavant and the Parkinson’s Foundation Collaborate to Better Understand Parkinson’s Research | New

NEW YORK and SAN FRANCISCO, July 19. 12, 2022 (GLOBE NEWSWIRE) — Daavant, the leader in helping organizations securely connect health data, and the Parkinson’s Foundation, a national nonprofit dedicated to improving the lives of people with Parkinson’s disease. (MP), announced a partnership that will further develop PD patient registries and foster participation in industry-sponsored research.

“We are thrilled to partner with the Parkinson Foundation, which is a global leader enabling research into Parkinson’s disease and improving the lives of people living with the disease,” said Travis May, Founder and Chairman of Datavant. “Enabling new links between clinical and genomic datasets will help advance biomarker-based research into the causes and treatment of Parkinson’s disease.”

The Parkinson’s Foundation will use Datavant’s privacy technology to link multiple datasets to two key clinical studies: Parkinson’s Outcomes Project, a clinic-based longitudinal natural history registry with 13,000 participants living with Parkinsons, and PD GENEration: Mapping the future of Parkinson’s disease, a one-of-a-kind national initiative that provides free genetic testing and counseling for seven PD-related genes to people with a confirmed diagnosis of PD. The PD GENEration study recently expanded to nearly 100 sites — while still offering home testing — as part of the Foundation’s commitment to reach new populations. Thanks to Datavant, the two studies will be able to share anonymized clinical data for future research related to PD.

“We hope to provide the research community with tools and a library of data that will help advance Parkinson’s disease research, create breakthroughs in treatment, and improve care for people living with Parkinson’s disease.” , said James Beck, PhD, scientific director of the Parkinson’s Foundation. .

The goal of the study is to improve PD care by accelerating and supporting research to advance improved treatments and personalized medicine. The study aims to help people with PD and their doctors determine if they are eligible to enroll in certain clinical trials based on their results. Currently at 28% of its goal of 15,000 participants, study participants are enrolled in all 50 U.S. states, Puerto Rico, and the Dominican Republic.

For more information on the Foundation’s research strategy, visit parkinson.org/research.

About the Parkinson Foundation

The Parkinson Foundation improves the lives of people with Parkinson’s disease by improving care and advancing the search for a cure. In everything we do, we draw on the energy, experience and passion of our global Parkinson’s community. Since 1957, the Parkinson Foundation has invested more than $400 million in research and clinical care for Parkinson’s disease. Join us on parkinson.org, Facebook, Twitter, instagram or call (800) 4PD-INFO (473-4636).

About Parkinson’s disease

Affecting approximately one million Americans and 10 million worldwide, Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s disease and the 14th leading cause of death in the United States. It is associated with progressive loss of motor control (eg, tremors or tremors at rest and lack of facial expression), as well as non-motor symptoms (eg, depression and anxiety). Parkinson’s disease is incurable and 60,000 new cases are diagnosed each year in the United States alone.

About Datavant

Datavant’s mission is to connect global health data to improve patient outcomes. Datavant strives to reduce the friction of data sharing in the healthcare industry by developing technology that protects patient privacy while supporting the linking of patient health records between datasets. Learn more about Datavant at www.dataavant.com.

Media contacts:

Marissa Cruz

Public Relations Manager, Parkinson Foundation

[email protected]

Larine Hamied

Partner Marketing Manager, Datavant

[email protected]

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.